Barclays PLC Increases Stock Holdings in OmniAb, Inc. (NASDAQ:OABI)

Barclays PLC boosted its stake in shares of OmniAb, Inc. (NASDAQ:OABIFree Report) by 321.5% during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 143,215 shares of the company’s stock after buying an additional 109,236 shares during the period. Barclays PLC owned approximately 0.12% of OmniAb worth $606,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Isthmus Partners LLC increased its position in OmniAb by 37.2% during the second quarter. Isthmus Partners LLC now owns 528,385 shares of the company’s stock valued at $1,981,000 after acquiring an additional 143,387 shares during the last quarter. American Century Companies Inc. grew its holdings in OmniAb by 52.7% during the 2nd quarter. American Century Companies Inc. now owns 110,036 shares of the company’s stock valued at $413,000 after purchasing an additional 37,963 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in OmniAb by 6.9% during the 2nd quarter. Dimensional Fund Advisors LP now owns 3,012,216 shares of the company’s stock valued at $11,296,000 after purchasing an additional 194,835 shares during the last quarter. Sei Investments Co. raised its position in OmniAb by 11.0% in the 2nd quarter. Sei Investments Co. now owns 29,024 shares of the company’s stock worth $109,000 after purchasing an additional 2,888 shares during the period. Finally, Squarepoint Ops LLC bought a new stake in OmniAb in the second quarter worth about $449,000. 72.08% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently commented on OABI. Benchmark reaffirmed a “buy” rating and set a $8.00 target price on shares of OmniAb in a research note on Thursday, November 14th. HC Wainwright reaffirmed a “buy” rating and issued a $11.00 price objective on shares of OmniAb in a research report on Thursday, November 14th.

Check Out Our Latest Stock Analysis on OmniAb

OmniAb Price Performance

Shares of OABI stock opened at $3.54 on Thursday. The company has a market capitalization of $499.90 million, a P/E ratio of -5.71 and a beta of -0.14. The company’s 50-day simple moving average is $3.92 and its two-hundred day simple moving average is $4.12. OmniAb, Inc. has a one year low of $3.43 and a one year high of $6.72.

OmniAb Profile

(Free Report)

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.

Featured Articles

Want to see what other hedge funds are holding OABI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OmniAb, Inc. (NASDAQ:OABIFree Report).

Institutional Ownership by Quarter for OmniAb (NASDAQ:OABI)

Receive News & Ratings for OmniAb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OmniAb and related companies with MarketBeat.com's FREE daily email newsletter.